The effect of acetaminophen on ischemia- reperfusion injery in patients with ST segment elevation acute myocardial infarction treated by primary percutaneous coronary intervention

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017011828454N3

Enrollment

Registered

2017-02-11

Start date

2017-02-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST segment elevation acute myocardial infarction. Acute myocardial infarction

Interventions

Case group receive 1 gram paracetamol before primary percutaneous coronary intervention.

Treatment - Drugs

Case group receive 1 gram paracetamol before primary percutaneous coronary intervention

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria include: patient willingness to take part in the study, informed consent, age above 20 and below 65 years and include all patients with STEMI. Exclusion criteria included a history of kidney and liver disease, acute hepatitis, asthma, pregnancy, cardiac output less than 30%, history of heart failure, and consumption of acetaminophen, warfarin, salicylates, barbiturates, carbamazepine, hydantoin and rifampin, rifabutin, isoniazid, alcohol, and antioxidants drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Homocysteine. Timepoint: Before and after primaryprecutanous coronary intervention. Method of measurement: Measuring the level of homocysteine in coronary blood sample.;Glutathione. Timepoint: Before and after primaryprecutanous coronary intervention. Method of measurement: Measuring the level of Glutathionein coronary blood sample.;Malondialdehyde. Timepoint: Before and after primaryprecutanous coronary intervention. Method of measurement: Measuring the level of malondialdehydecoronary blood sample.	—

Measure

Time frame

Homocysteine. Timepoint: Before and after primaryprecutanous coronary intervention. Method of measurement: Measuring the level of homocysteine in coronary blood sample.;Glutathione. Timepoint: Before and after primaryprecutanous coronary intervention. Method of measurement: Measuring the level of Glutathionein coronary blood sample.;Malondialdehyde. Timepoint: Before and after primaryprecutanous coronary intervention. Method of measurement: Measuring the level of malondialdehydecoronary blood sample.

—

Secondary

Measure	Time frame
LDH. Timepoint: Before and six hours after primary precutaneous coronary intervention. Method of measurement: Measuring the level of LDH from peripheral blood serum.;Troponine. Timepoint: Before and six hours after primary precutaneous coronary intervention. Method of measurement: Measuring the level of troponinefrom peripheral blood serum.;CPK-mb. Timepoint: Before and six hours after primary precutaneous coronary intervention. Method of measurement: Measuring the level of CPK-mb from peripheral blood serum.;CPK. Timepoint: Before and six hours after primary precutaneous coronary intervention. Method of measurement: Measuring the level of CPK from peripheral blood serum.	—

Measure

Time frame

LDH. Timepoint: Before and six hours after primary precutaneous coronary intervention. Method of measurement: Measuring the level of LDH from peripheral blood serum.;Troponine. Timepoint: Before and six hours after primary precutaneous coronary intervention. Method of measurement: Measuring the level of troponinefrom peripheral blood serum.;CPK-mb. Timepoint: Before and six hours after primary precutaneous coronary intervention. Method of measurement: Measuring the level of CPK-mb from peripheral blood serum.;CPK. Timepoint: Before and six hours after primary precutaneous coronary intervention. Method of measurement: Measuring the level of CPK from peripheral blood serum.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtefeh Asadmobini

Kermanshah University of medical Science

a.asadmobini@gmail.com+98 83 3839 5970

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026